$BLCO

Bausch & Lomb Corp (BLCO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance VAUGHAN, Ontario, Oct. 12, 2026 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its pa

Bausch + Lomb (BLCO) fell 9.13% to $15.72 after appointing Thomas J. Appio as interim CEO. Brent Saunders departed following a mutual agreement. The company also raised its 2026 adjusted EBITDA guidance, citing strong Q3 performance. Shares have traded between $14.39 and $18.92 in the past year.

RBC Capital reiterated an Outperform rating and $21.00 price target on Bausch & Lomb (NYSE:BLCO), projecting Q3 2026 revenue of $1,375M and adjusted EBITDA of $275M. The company reported Q2 2026 revenue of $1.394B, up 9.1% YoY, and raised full-year guidance. Analysts predict 2026 EPS of $0.82. Key focus areas include dry eye disease treatments and upcoming product launches.

Bausch + Lomb Corp (BLCO) announced progress in developing BL1243, an oral treatment for dry age-related macular degeneration, following a positive FDA meeting. The company plans to start clinical trials in 2027. BLCO's P/S ratio is 1.18, below its historical median, and it has a GF Score of 60/100, indicating mixed financial health. Insider activity and guru holdings show balanced sentiment.

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Bausch + Lomb (BLCO) received European CE Mark approval for SeeLyra, a next-gen femtosecond laser. It will launch in Europe soon and seek global approvals, including in the U.S. SeeLyra aids in cataract, LASIK, and corneal surgeries. BLCO shares closed at $17.55 on NYSE.

Bausch + Lomb (BLCO) reported positive real-world outcomes for its intraocular lenses, supporting its products' safety and effectiveness. The company's stock has seen significant gains, with a 20.19% total return over the past year. Investors are evaluating whether the current valuation, at $18.04 per share, leaves room for further upside, given a fair value estimate of $39.23 per share and ongoing governance concerns.

Bausch + Lomb (NYSE/TSX: BLCO) published research in Ophthalmology and Therapy showing enVista Aspire and enVista Aspire toric intraocular lenses provide good distance and intermediate vision in cataract patients. The study involved 84 patients and found high rates of visual acuity improvement with no serious adverse events. The lenses are designed to meet modern digital demands.

Healthcare stocks have outperformed the S&P 500, but some companies face challenges. Bausch + Lomb (BLCO) has declining EPS and free cash flow margins. Envista (NVST) shows weak sales growth and profitability. Progyny (PGNY) struggles with unit sales and capital returns. All three trade at forward P/E ratios of 16.9x, 17.5x, and 11.8x respectively.

Bausch + Lomb (NYSE/TSX: BLCO) announced two eye health therapies will advance to new trials. A dual-action eye drop for dry eye disease will move to Phase 3 after showing significant results at Day 15. An ocular surface pain treatment, BL1332, showed positive Phase 1b results and is in Phase 2 trials. Combined potential peak sales are estimated at over $2 billion.